#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Disturbances across whole brain networks during reward anticipation in an abstinent addiction population
#Text=Graphical abstract
#Text=Network based statistics (NBS) analyses detected a graph sub-network comprising 153 edges between 59 nodes of the connectome where the ADD group demonstrated significantly less connectivity compared with the CON group.
1-1	0-12	Disturbances	_	
1-2	13-19	across	_	
1-3	20-25	whole	_	
1-4	26-31	brain	_	
1-5	32-40	networks	_	
1-6	41-47	during	_	
1-7	48-54	reward	_	
1-8	55-67	anticipation	_	
1-9	68-70	in	_	
1-10	71-73	an	_	
1-11	74-83	abstinent	_	
1-12	84-93	addiction	_	
1-13	94-104	population	_	
1-14	105-114	Graphical	_	
1-15	115-123	abstract	_	
1-16	124-131	Network	_	
1-17	132-137	based	_	
1-18	138-148	statistics	_	
1-19	149-150	(	_	
1-20	150-153	NBS	_	
1-21	153-154	)	_	
1-22	155-163	analyses	_	
1-23	164-172	detected	_	
1-24	173-174	a	_	
1-25	175-180	graph	_	
1-26	181-192	sub-network	_	
1-27	193-203	comprising	_	
1-28	204-207	153	_	
1-29	208-213	edges	_	
1-30	214-221	between	_	
1-31	222-224	59	_	
1-32	225-230	nodes	_	
1-33	231-233	of	_	
1-34	234-237	the	_	
1-35	238-248	connectome	_	
1-36	249-254	where	_	
1-37	255-258	the	_	
1-38	259-262	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
1-39	263-268	group	_	
1-40	269-281	demonstrated	_	
1-41	282-295	significantly	_	
1-42	296-300	less	_	
1-43	301-313	connectivity	_	
1-44	314-322	compared	_	
1-45	323-327	with	_	
1-46	328-331	the	_	
1-47	332-335	CON	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
1-48	336-341	group	_	
1-49	341-342	.	_	

#Text=These differences in connectivity were mostly intra-hemispheric (55%), the majority (38%) being in the right hemisphere.
2-1	343-348	These	_	
2-2	349-360	differences	_	
2-3	361-363	in	_	
2-4	364-376	connectivity	_	
2-5	377-381	were	_	
2-6	382-388	mostly	_	
2-7	389-406	intra-hemispheric	_	
2-8	407-408	(	_	
2-9	408-411	55%	_	
2-10	411-412	)	_	
2-11	412-413	,	_	
2-12	414-417	the	_	
2-13	418-426	majority	_	
2-14	427-428	(	_	
2-15	428-431	38%	_	
2-16	431-432	)	_	
2-17	433-438	being	_	
2-18	439-441	in	_	
2-19	442-445	the	_	
2-20	446-451	right	_	
2-21	452-462	hemisphere	_	
2-22	462-463	.	_	

#Text=The anatomical distribution of these connectivity differences between the two groups involved frontal (insula, inferior frontal gyrus, orbitofrontal cortex), limbic-associated (anterior cingulate gyrus, thalamus), and striatal (accumbens, caudate, pallidum) regions.
3-1	464-467	The	_	
3-2	468-478	anatomical	_	
3-3	479-491	distribution	_	
3-4	492-494	of	_	
3-5	495-500	these	_	
3-6	501-513	connectivity	_	
3-7	514-525	differences	_	
3-8	526-533	between	_	
3-9	534-537	the	_	
3-10	538-541	two	_	
3-11	542-548	groups	_	
3-12	549-557	involved	_	
3-13	558-565	frontal	_	
3-14	566-567	(	_	
3-15	567-573	insula	_	
3-16	573-574	,	_	
3-17	575-583	inferior	_	
3-18	584-591	frontal	_	
3-19	592-597	gyrus	_	
3-20	597-598	,	_	
3-21	599-612	orbitofrontal	_	
3-22	613-619	cortex	_	
3-23	619-620	)	_	
3-24	620-621	,	_	
3-25	622-639	limbic-associated	_	
3-26	640-641	(	_	
3-27	641-649	anterior	_	
3-28	650-659	cingulate	_	
3-29	660-665	gyrus	_	
3-30	665-666	,	_	
3-31	667-675	thalamus	_	
3-32	675-676	)	_	
3-33	676-677	,	_	
3-34	678-681	and	_	
3-35	682-690	striatal	_	
3-36	691-692	(	_	
3-37	692-701	accumbens	_	
3-38	701-702	,	_	
3-39	703-710	caudate	_	
3-40	710-711	,	_	
3-41	712-720	pallidum	_	
3-42	720-721	)	_	
3-43	722-729	regions	_	
3-44	729-730	.	_	

#Text=The connectivity differences reported in this ADD sample indicate alterations between cognitive, striatal and limbic-associated regions during reward anticipation that persist into extended abstinence.
4-1	731-734	The	_	
4-2	735-747	connectivity	_	
4-3	748-759	differences	_	
4-4	760-768	reported	_	
4-5	769-771	in	_	
4-6	772-776	this	_	
4-7	777-780	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[3]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
4-8	781-787	sample	_	
4-9	788-796	indicate	_	
4-10	797-808	alterations	_	
4-11	809-816	between	_	
4-12	817-826	cognitive	_	
4-13	826-827	,	_	
4-14	828-836	striatal	_	
4-15	837-840	and	_	
4-16	841-858	limbic-associated	_	
4-17	859-866	regions	_	
4-18	867-873	during	_	
4-19	874-880	reward	_	
4-20	881-893	anticipation	_	
4-21	894-898	that	_	
4-22	899-906	persist	_	
4-23	907-911	into	_	
4-24	912-920	extended	_	
4-25	921-931	abstinence	_	
4-26	931-932	.	_	

#Text=Highlights
#Text=Analytical methods can capture key features of whole brain networks in addiction.
5-1	933-943	Highlights	_	
5-2	944-954	Analytical	_	
5-3	955-962	methods	_	
5-4	963-966	can	_	
5-5	967-974	capture	_	
5-6	975-978	key	_	
5-7	979-987	features	_	
5-8	988-990	of	_	
5-9	991-996	whole	_	
5-10	997-1002	brain	_	
5-11	1003-1011	networks	_	
5-12	1012-1014	in	_	
5-13	1015-1024	addiction	_	
5-14	1024-1025	.	_	

#Text=We compared reward network connectivity in addiction (ADD) and control (CON) groups.
6-1	1026-1028	We	_	
6-2	1029-1037	compared	_	
6-3	1038-1044	reward	_	
6-4	1045-1052	network	_	
6-5	1053-1065	connectivity	_	
6-6	1066-1068	in	_	
6-7	1069-1078	addiction	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
6-8	1079-1080	(	_	
6-9	1080-1083	ADD	_	
6-10	1083-1084	)	_	
6-11	1085-1088	and	_	
6-12	1089-1096	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-13	1097-1098	(	_	
6-14	1098-1101	CON	_	
6-15	1101-1102	)	_	
6-16	1103-1109	groups	_	
6-17	1109-1110	.	_	

#Text=The ADD group showed disruptions in global network connectivity.
7-1	1111-1114	The	_	
7-2	1115-1118	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[7]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
7-3	1119-1124	group	_	
7-4	1125-1131	showed	_	
7-5	1132-1143	disruptions	_	
7-6	1144-1146	in	_	
7-7	1147-1153	global	_	
7-8	1154-1161	network	_	
7-9	1162-1174	connectivity	_	
7-10	1174-1175	.	_	

#Text=Global network measures may be more sensitive than traditional voxel-wise analyses.
8-1	1176-1182	Global	_	
8-2	1183-1190	network	_	
8-3	1191-1199	measures	_	
8-4	1200-1203	may	_	
8-5	1204-1206	be	_	
8-6	1207-1211	more	_	
8-7	1212-1221	sensitive	_	
8-8	1222-1226	than	_	
8-9	1227-1238	traditional	_	
8-10	1239-1249	voxel-wise	_	
8-11	1250-1258	analyses	_	
8-12	1258-1259	.	_	

#Text=The prevalent spatial distribution of abnormalities reported in cognitive fMRI studies in addiction suggests there are extensive disruptions across whole brain networks.
9-1	1260-1263	The	_	
9-2	1264-1273	prevalent	_	
9-3	1274-1281	spatial	_	
9-4	1282-1294	distribution	_	
9-5	1295-1297	of	_	
9-6	1298-1311	abnormalities	_	
9-7	1312-1320	reported	_	
9-8	1321-1323	in	_	
9-9	1324-1333	cognitive	_	
9-10	1334-1338	fMRI	_	
9-11	1339-1346	studies	_	
9-12	1347-1349	in	_	
9-13	1350-1359	addiction	_	
9-14	1360-1368	suggests	_	
9-15	1369-1374	there	_	
9-16	1375-1378	are	_	
9-17	1379-1388	extensive	_	
9-18	1389-1400	disruptions	_	
9-19	1401-1407	across	_	
9-20	1408-1413	whole	_	
9-21	1414-1419	brain	_	
9-22	1420-1428	networks	_	
9-23	1428-1429	.	_	

#Text=Studies using resting state have reported disruptions in network connectivity in addiction, but these studies have not revealed characteristics of network functioning during critical psychological processes that are disrupted in addiction populations.
10-1	1430-1437	Studies	_	
10-2	1438-1443	using	_	
10-3	1444-1451	resting	_	
10-4	1452-1457	state	_	
10-5	1458-1462	have	_	
10-6	1463-1471	reported	_	
10-7	1472-1483	disruptions	_	
10-8	1484-1486	in	_	
10-9	1487-1494	network	_	
10-10	1495-1507	connectivity	_	
10-11	1508-1510	in	_	
10-12	1511-1520	addiction	_	
10-13	1520-1521	,	_	
10-14	1522-1525	but	_	
10-15	1526-1531	these	_	
10-16	1532-1539	studies	_	
10-17	1540-1544	have	_	
10-18	1545-1548	not	_	
10-19	1549-1557	revealed	_	
10-20	1558-1573	characteristics	_	
10-21	1574-1576	of	_	
10-22	1577-1584	network	_	
10-23	1585-1596	functioning	_	
10-24	1597-1603	during	_	
10-25	1604-1612	critical	_	
10-26	1613-1626	psychological	_	
10-27	1627-1636	processes	_	
10-28	1637-1641	that	_	
10-29	1642-1645	are	_	
10-30	1646-1655	disrupted	_	
10-31	1656-1658	in	_	
10-32	1659-1668	addiction	_	
10-33	1669-1680	populations	_	
10-34	1680-1681	.	_	

#Text=Analytic methods that can capture key features of whole brain networks during psychological processes may be more sensitive in revealing additional and widespread neural disturbances in addiction, that are the provisions for relapse risk, and targets for medication development.
11-1	1682-1690	Analytic	_	
11-2	1691-1698	methods	_	
11-3	1699-1703	that	_	
11-4	1704-1707	can	_	
11-5	1708-1715	capture	_	
11-6	1716-1719	key	_	
11-7	1720-1728	features	_	
11-8	1729-1731	of	_	
11-9	1732-1737	whole	_	
11-10	1738-1743	brain	_	
11-11	1744-1752	networks	_	
11-12	1753-1759	during	_	
11-13	1760-1773	psychological	_	
11-14	1774-1783	processes	_	
11-15	1784-1787	may	_	
11-16	1788-1790	be	_	
11-17	1791-1795	more	_	
11-18	1796-1805	sensitive	_	
11-19	1806-1808	in	_	
11-20	1809-1818	revealing	_	
11-21	1819-1829	additional	_	
11-22	1830-1833	and	_	
11-23	1834-1844	widespread	_	
11-24	1845-1851	neural	_	
11-25	1852-1864	disturbances	_	
11-26	1865-1867	in	_	
11-27	1868-1877	addiction	_	
11-28	1877-1878	,	_	
11-29	1879-1883	that	_	
11-30	1884-1887	are	_	
11-31	1888-1891	the	_	
11-32	1892-1902	provisions	_	
11-33	1903-1906	for	_	
11-34	1907-1914	relapse	_	
11-35	1915-1919	risk	_	
11-36	1919-1920	,	_	
11-37	1921-1924	and	_	
11-38	1925-1932	targets	_	
11-39	1933-1936	for	_	
11-40	1937-1947	medication	_	
11-41	1948-1959	development	_	
11-42	1959-1960	.	_	

#Text=The current study compared a substance addiction (ADD; n = 83) group in extended abstinence with a control (CON; n = 68) group on functional MRI (voxel-wise activation) and global network (connectivity) measures related to reward anticipation on a monetary incentive delay task.
12-1	1961-1964	The	_	
12-2	1965-1972	current	_	
12-3	1973-1978	study	_	
12-4	1979-1987	compared	_	
12-5	1988-1989	a	_	
12-6	1990-1999	substance	_	
12-7	2000-2009	addiction	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]	
12-8	2010-2011	(	_	
12-9	2011-2014	ADD	_	
12-10	2014-2015	;	_	
12-11	2016-2017	n	_	
12-12	2017-2018	 	_	
12-13	2018-2019	=	_	
12-14	2019-2020	 	_	
12-15	2020-2022	83	_	
12-16	2022-2023	)	_	
12-17	2024-2029	group	_	
12-18	2030-2032	in	_	
12-19	2033-2041	extended	_	
12-20	2042-2052	abstinence	_	
12-21	2053-2057	with	_	
12-22	2058-2059	a	_	
12-23	2060-2067	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
12-24	2068-2069	(	_	
12-25	2069-2072	CON	_	
12-26	2072-2073	;	_	
12-27	2074-2075	n	_	
12-28	2075-2076	 	_	
12-29	2076-2077	=	_	
12-30	2077-2078	 	_	
12-31	2078-2080	68	_	
12-32	2080-2081	)	_	
12-33	2082-2087	group	_	
12-34	2088-2090	on	_	
12-35	2091-2101	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
12-36	2102-2105	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
12-37	2106-2107	(	_	
12-38	2107-2117	voxel-wise	_	
12-39	2118-2128	activation	_	
12-40	2128-2129	)	_	
12-41	2130-2133	and	_	
12-42	2134-2140	global	_	
12-43	2141-2148	network	_	
12-44	2149-2150	(	_	
12-45	2150-2162	connectivity	_	
12-46	2162-2163	)	_	
12-47	2164-2172	measures	_	
12-48	2173-2180	related	_	
12-49	2181-2183	to	_	
12-50	2184-2190	reward	_	
12-51	2191-2203	anticipation	_	
12-52	2204-2206	on	_	
12-53	2207-2208	a	_	
12-54	2209-2217	monetary	_	
12-55	2218-2227	incentive	_	
12-56	2228-2233	delay	_	
12-57	2234-2238	task	_	
12-58	2238-2239	.	_	

#Text=In the absence of group differences on MID performance, the ADD group showed reduced activation predominantly across temporal and visual regions, but not across the striatum.
13-1	2240-2242	In	_	
13-2	2243-2246	the	_	
13-3	2247-2254	absence	_	
13-4	2255-2257	of	_	
13-5	2258-2263	group	_	
13-6	2264-2275	differences	_	
13-7	2276-2278	on	_	
13-8	2279-2282	MID	_	
13-9	2283-2294	performance	_	
13-10	2294-2295	,	_	
13-11	2296-2299	the	_	
13-12	2300-2303	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[12]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[13]	
13-13	2304-2309	group	_	
13-14	2310-2316	showed	_	
13-15	2317-2324	reduced	_	
13-16	2325-2335	activation	_	
13-17	2336-2349	predominantly	_	
13-18	2350-2356	across	_	
13-19	2357-2365	temporal	_	
13-20	2366-2369	and	_	
13-21	2370-2376	visual	_	
13-22	2377-2384	regions	_	
13-23	2384-2385	,	_	
13-24	2386-2389	but	_	
13-25	2390-2393	not	_	
13-26	2394-2400	across	_	
13-27	2401-2404	the	_	
13-28	2405-2413	striatum	_	
13-29	2413-2414	.	_	

#Text=The ADD group also showed disruptions in global network connectivity (lower clustering coefficient and higher characteristic path length), and significantly less connectivity across a sub-network comprising frontal, temporal, limbic and striatal nodes.
14-1	2415-2418	The	_	
14-2	2419-2422	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[14]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
14-3	2423-2428	group	_	
14-4	2429-2433	also	_	
14-5	2434-2440	showed	_	
14-6	2441-2452	disruptions	_	
14-7	2453-2455	in	_	
14-8	2456-2462	global	_	
14-9	2463-2470	network	_	
14-10	2471-2483	connectivity	_	
14-11	2484-2485	(	_	
14-12	2485-2490	lower	_	
14-13	2491-2501	clustering	_	
14-14	2502-2513	coefficient	_	
14-15	2514-2517	and	_	
14-16	2518-2524	higher	_	
14-17	2525-2539	characteristic	_	
14-18	2540-2544	path	_	
14-19	2545-2551	length	_	
14-20	2551-2552	)	_	
14-21	2552-2553	,	_	
14-22	2554-2557	and	_	
14-23	2558-2571	significantly	_	
14-24	2572-2576	less	_	
14-25	2577-2589	connectivity	_	
14-26	2590-2596	across	_	
14-27	2597-2598	a	_	
14-28	2599-2610	sub-network	_	
14-29	2611-2621	comprising	_	
14-30	2622-2629	frontal	_	
14-31	2629-2630	,	_	
14-32	2631-2639	temporal	_	
14-33	2639-2640	,	_	
14-34	2641-2647	limbic	_	
14-35	2648-2651	and	_	
14-36	2652-2660	striatal	_	
14-37	2661-2666	nodes	_	
14-38	2666-2667	.	_	

#Text=These results show that an addiction group in extended abstinence exhibit localised disruptions in brain activation, but more extensive disturbances in functional connectivity across whole brain networks.
15-1	2668-2673	These	_	
15-2	2674-2681	results	_	
15-3	2682-2686	show	_	
15-4	2687-2691	that	_	
15-5	2692-2694	an	_	
15-6	2695-2704	addiction	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[17]	
15-7	2705-2710	group	_	
15-8	2711-2713	in	_	
15-9	2714-2722	extended	_	
15-10	2723-2733	abstinence	_	
15-11	2734-2741	exhibit	_	
15-12	2742-2751	localised	_	
15-13	2752-2763	disruptions	_	
15-14	2764-2766	in	_	
15-15	2767-2772	brain	_	
15-16	2773-2783	activation	_	
15-17	2783-2784	,	_	
15-18	2785-2788	but	_	
15-19	2789-2793	more	_	
15-20	2794-2803	extensive	_	
15-21	2804-2816	disturbances	_	
15-22	2817-2819	in	_	
15-23	2820-2830	functional	_	
15-24	2831-2843	connectivity	_	
15-25	2844-2850	across	_	
15-26	2851-2856	whole	_	
15-27	2857-2862	brain	_	
15-28	2863-2871	networks	_	
15-29	2871-2872	.	_	

#Text=We propose that measures of global network functioning may be more sensitive in highlighting latent and more widespread neural disruptions during critical psychological processes in addiction and other psychiatric disorders.
16-1	2873-2875	We	_	
16-2	2876-2883	propose	_	
16-3	2884-2888	that	_	
16-4	2889-2897	measures	_	
16-5	2898-2900	of	_	
16-6	2901-2907	global	_	
16-7	2908-2915	network	_	
16-8	2916-2927	functioning	_	
16-9	2928-2931	may	_	
16-10	2932-2934	be	_	
16-11	2935-2939	more	_	
16-12	2940-2949	sensitive	_	
16-13	2950-2952	in	_	
16-14	2953-2965	highlighting	_	
16-15	2966-2972	latent	_	
16-16	2973-2976	and	_	
16-17	2977-2981	more	_	
16-18	2982-2992	widespread	_	
16-19	2993-2999	neural	_	
16-20	3000-3011	disruptions	_	
16-21	3012-3018	during	_	
16-22	3019-3027	critical	_	
16-23	3028-3041	psychological	_	
16-24	3042-3051	processes	_	
16-25	3052-3054	in	_	
16-26	3055-3064	addiction	_	
16-27	3065-3068	and	_	
16-28	3069-3074	other	_	
16-29	3075-3086	psychiatric	_	
16-30	3087-3096	disorders	_	
16-31	3096-3097	.	_	



#Text=Material and methods
#Text=Participants
#Text=Sixty-eight control (CON: mean age 39.79 ± 1.22; 18 females, 50 males) and 83 addiction (ADD: mean age 40.05 ± 0.92; 16 females, 67 males) participants completed the current study.
31-1	6090-6098	Material	_	
31-2	6099-6102	and	_	
31-3	6103-6110	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
31-4	6111-6123	Participants	_	
31-5	6124-6135	Sixty-eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-6	6136-6143	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
31-7	6144-6145	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-8	6145-6148	CON	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-9	6148-6149	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-10	6150-6154	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-11	6155-6158	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-12	6159-6164	39.79	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-13	6164-6165	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-14	6165-6166	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-15	6166-6167	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-16	6167-6171	1.22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-17	6171-6172	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-18	6173-6175	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-19	6176-6183	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-20	6183-6184	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-21	6185-6187	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-22	6188-6193	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-23	6193-6194	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-24	6195-6198	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-25	6199-6201	83	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-26	6202-6211	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[20]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[21]	
31-27	6212-6213	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-28	6213-6216	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-29	6216-6217	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-30	6218-6222	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-31	6223-6226	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-32	6227-6232	40.05	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-33	6232-6233	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-34	6233-6234	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-35	6234-6235	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-36	6235-6239	0.92	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-37	6239-6240	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-38	6241-6243	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-39	6244-6251	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-40	6251-6252	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-41	6253-6255	67	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-42	6256-6261	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-43	6261-6262	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-44	6263-6275	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-45	6276-6285	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-46	6286-6289	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-47	6290-6297	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-48	6298-6303	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-49	6303-6304	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The current dataset was collected as part of a multi-centre study involving three study sites in the United Kingdom (Imperial College London, University of Cambridge and University of Manchester – ICCAM).
32-1	6305-6308	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-2	6309-6316	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-3	6317-6324	dataset	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-4	6325-6328	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-5	6329-6338	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-6	6339-6341	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-7	6342-6346	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-8	6347-6349	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-9	6350-6351	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-10	6352-6364	multi-centre	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-11	6365-6370	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-12	6371-6380	involving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-13	6381-6386	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-14	6387-6392	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-15	6393-6398	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-16	6399-6401	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-17	6402-6405	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-18	6406-6412	United	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-19	6413-6420	Kingdom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-20	6421-6422	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-21	6422-6430	Imperial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-22	6431-6438	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-23	6439-6445	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-24	6445-6446	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-25	6447-6457	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-26	6458-6460	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-27	6461-6470	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-28	6471-6474	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-29	6475-6485	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-30	6486-6488	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-31	6489-6499	Manchester	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-32	6500-6501	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-33	6502-6507	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-34	6507-6508	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-35	6508-6509	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=For a more detailed description of the ICCAM Platform, see) and.
33-1	6510-6513	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-2	6514-6515	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-3	6516-6520	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-4	6521-6529	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-5	6530-6541	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-6	6542-6544	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-7	6545-6548	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-8	6549-6554	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-9	6555-6563	Platform	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-10	6563-6564	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-11	6565-6568	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-12	6568-6569	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-13	6570-6573	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-14	6573-6574	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Inclusion criteria were individuals who met DSM-IV measures for current or prior substance dependence (e.g., alcohol, cocaine, opiates).
34-1	6575-6584	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-2	6585-6593	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-3	6594-6598	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-4	6599-6610	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-5	6611-6614	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-6	6615-6618	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-7	6619-6625	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-8	6626-6634	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-9	6635-6638	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-10	6639-6646	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-11	6647-6649	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-12	6650-6655	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-13	6656-6665	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-14	6666-6676	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-15	6677-6678	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-16	6678-6681	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-17	6681-6682	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-18	6682-6683	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-19	6684-6691	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-20	6691-6692	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-21	6693-6700	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-22	6700-6701	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-23	6702-6709	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-24	6709-6710	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-25	6710-6711	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The ADD group consisted of 29 (35%) pure alcohol-dependent, 42 (50%) poly substance-dependent (e.g., alcohol and cocaine, cocaine and opiate) and 12 (15%) mono substance-dependent (e.g., cocaine, opiates) volunteers.
35-1	6712-6715	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-2	6716-6719	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[22]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[23]	
35-3	6720-6725	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-4	6726-6735	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-5	6736-6738	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-6	6739-6741	29	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-7	6742-6743	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-8	6743-6746	35%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-9	6746-6747	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-10	6748-6752	pure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-11	6753-6770	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-12	6770-6771	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-13	6772-6774	42	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-14	6775-6776	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-15	6776-6779	50%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-16	6779-6780	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-17	6781-6785	poly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-18	6786-6805	substance-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-19	6806-6807	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-20	6807-6810	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-21	6810-6811	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-22	6811-6812	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-23	6813-6820	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-24	6821-6824	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-25	6825-6832	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-26	6832-6833	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-27	6834-6841	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-28	6842-6845	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-29	6846-6852	opiate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-30	6852-6853	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-31	6854-6857	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-32	6858-6860	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-33	6861-6862	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-34	6862-6865	15%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-35	6865-6866	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-36	6867-6871	mono	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-37	6872-6891	substance-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-38	6892-6893	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-39	6893-6896	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-40	6896-6897	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-41	6897-6898	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-42	6899-6906	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-43	6906-6907	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-44	6908-6915	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-45	6915-6916	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-46	6917-6927	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-47	6927-6928	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=While addiction studies typically recruit volunteers in early abstinence, there was no upper limit in the current study.
36-1	6929-6934	While	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-2	6935-6944	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-3	6945-6952	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-4	6953-6962	typically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-5	6963-6970	recruit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-6	6971-6981	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-7	6982-6984	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-8	6985-6990	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-9	6991-7001	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-10	7001-7002	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-11	7003-7008	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-12	7009-7012	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-13	7013-7015	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-14	7016-7021	upper	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-15	7022-7027	limit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-16	7028-7030	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-17	7031-7034	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-18	7035-7042	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-19	7043-7048	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-20	7048-7049	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The mean abstinence length from alcohol in the current sample was 15.00 ± 3.50 months, while for cocaine and opiates it was 27.99 ± 3.72 and 39.04 ± 7.75 months, respectively.
37-1	7050-7053	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-2	7054-7058	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-3	7059-7069	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-4	7070-7076	length	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-5	7077-7081	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-6	7082-7089	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-7	7090-7092	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-8	7093-7096	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-9	7097-7104	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-10	7105-7111	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-11	7112-7115	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-12	7116-7121	15.00	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-13	7121-7122	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-14	7122-7123	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-15	7123-7124	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-16	7124-7128	3.50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-17	7128-7129	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-18	7129-7135	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-19	7135-7136	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-20	7137-7142	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-21	7143-7146	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-22	7147-7154	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-23	7155-7158	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-24	7159-7166	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-25	7167-7169	it	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-26	7170-7173	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-27	7174-7179	27.99	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-28	7179-7180	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-29	7180-7181	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-30	7181-7182	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-31	7182-7186	3.72	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-32	7187-7190	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-33	7191-7196	39.04	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-34	7196-7197	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-35	7197-7198	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-36	7198-7199	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-37	7199-7203	7.75	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-38	7203-7204	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-39	7204-7210	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-40	7210-7211	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-41	7212-7224	respectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-42	7224-7225	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Therefore, the current ADD group was made of a heterogenous sample with former substance-dependencies, and with variable levels of substance abstinence at the time of testing.
38-1	7226-7235	Therefore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-2	7235-7236	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-3	7237-7240	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-4	7241-7248	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-5	7249-7252	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-6	7253-7258	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-7	7259-7262	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-8	7263-7267	made	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-9	7268-7270	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-10	7271-7272	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-11	7273-7285	heterogenous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-12	7286-7292	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-13	7293-7297	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-14	7298-7304	former	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-15	7305-7327	substance-dependencies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-16	7327-7328	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-17	7329-7332	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-18	7333-7337	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-19	7338-7346	variable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-20	7347-7353	levels	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-21	7354-7356	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-22	7357-7366	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-23	7367-7377	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-24	7378-7380	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-25	7381-7384	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-26	7385-7389	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-27	7390-7392	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-28	7393-7400	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-29	7400-7401	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=This meant that there was no substance dependence measure that was shared by all members of the ADD group.
39-1	7402-7406	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-2	7407-7412	meant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-3	7413-7417	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-4	7418-7423	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-5	7424-7427	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-6	7428-7430	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-7	7431-7440	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-8	7441-7451	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-9	7452-7459	measure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-10	7460-7464	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-11	7465-7468	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-12	7469-7475	shared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-13	7476-7478	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-14	7479-7482	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-15	7483-7490	members	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-16	7491-7493	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-17	7494-7497	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-18	7498-7501	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[24]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[25]	
39-19	7502-7507	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-20	7507-7508	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The CON group had no previous history of substance abuse, as assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and timeline follow-back.
40-1	7509-7512	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-2	7513-7516	CON	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
40-3	7517-7522	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-4	7523-7526	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-5	7527-7529	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-6	7530-7538	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-7	7539-7546	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-8	7547-7549	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-9	7550-7559	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-10	7560-7565	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-11	7565-7566	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-12	7567-7569	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-13	7570-7578	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-14	7579-7584	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-15	7585-7588	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-16	7589-7596	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-17	7596-7597	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-18	7598-7605	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-19	7606-7609	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-20	7610-7619	Substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-21	7620-7631	Involvement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-22	7632-7641	Screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-23	7642-7646	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-24	7647-7648	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-25	7648-7654	ASSIST	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-26	7654-7655	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-27	7656-7659	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-28	7660-7668	timeline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-29	7669-7680	follow-back	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-30	7680-7681	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=All participants were required to provide a negative breath alcohol test and a negative urine sample for various drugs of abuse on the day of testing (screening for the presence of amphetamines, benzodiazepines, cannabinoids, cocaine and opiates).
41-1	7682-7685	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-2	7686-7698	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-3	7699-7703	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-4	7704-7712	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-5	7713-7715	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-6	7716-7723	provide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-7	7724-7725	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-8	7726-7734	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-9	7735-7741	breath	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-10	7742-7749	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-11	7750-7754	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-12	7755-7758	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-13	7759-7760	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-14	7761-7769	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-15	7770-7775	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-16	7776-7782	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-17	7783-7786	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-18	7787-7794	various	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-19	7795-7800	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-20	7801-7803	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-21	7804-7809	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-22	7810-7812	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-23	7813-7816	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-24	7817-7820	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-25	7821-7823	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-26	7824-7831	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-27	7832-7833	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-28	7833-7842	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-29	7843-7846	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-30	7847-7850	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-31	7851-7859	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-32	7860-7862	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-33	7863-7875	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-34	7875-7876	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-35	7877-7892	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-36	7892-7893	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-37	7894-7906	cannabinoids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-38	7906-7907	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-39	7908-7915	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-40	7916-7919	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-41	7920-7927	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-42	7927-7928	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-43	7928-7929	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The Mini-International Neuropsychiatric Interview (MINI) was administered to all participants by a trained psychiatrist to screen for the presence of Axis I psychiatric disorders that were part of the study exclusion criteria.
42-1	7930-7933	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-2	7934-7952	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-3	7953-7969	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-4	7970-7979	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-5	7980-7981	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-6	7981-7985	MINI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-7	7985-7986	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-8	7987-7990	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-9	7991-8003	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-10	8004-8006	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-11	8007-8010	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-12	8011-8023	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-13	8024-8026	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-14	8027-8028	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-15	8029-8036	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-16	8037-8049	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-17	8050-8052	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-18	8053-8059	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-19	8060-8063	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-20	8064-8067	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-21	8068-8076	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-22	8077-8079	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-23	8080-8084	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-24	8085-8086	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-25	8087-8098	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-26	8099-8108	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-27	8109-8113	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-28	8114-8118	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-29	8119-8123	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-30	8124-8126	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-31	8127-8130	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-32	8131-8136	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-33	8137-8146	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-34	8147-8155	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-35	8155-8156	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Exclusion criteria included 1) current use of regular prescription or non-prescription medication that could not be stopped; 2) current primary axis I diagnosis, past history of psychosis (unless drug-induced); 3) current or past history of enduring severe mental illness (e.g., schizophrenia, bipolar affective disorder); 4) other current or past psychiatric history that, in the opinion of a psychiatrist, contraindicated participation; 5) history or presence of a significant neurological diagnosis that may have influenced the outcome or analysis of the results; 6) claustrophobia or unable to lie still in the MRI scanner for up to 90 min and 7) presence of a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre-MRI questionnaire.
43-1	8157-8166	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-2	8167-8175	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-3	8176-8184	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-4	8185-8186	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-5	8186-8187	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-6	8188-8195	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-7	8196-8199	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-8	8200-8202	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-9	8203-8210	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-10	8211-8223	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-11	8224-8226	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-12	8227-8243	non-prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-13	8244-8254	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-14	8255-8259	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-15	8260-8265	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-16	8266-8269	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-17	8270-8272	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-18	8273-8280	stopped	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-19	8280-8281	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-20	8282-8283	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-21	8283-8284	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-22	8285-8292	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-23	8293-8300	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-24	8301-8305	axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-25	8306-8307	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-26	8308-8317	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-27	8317-8318	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-28	8319-8323	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-29	8324-8331	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-30	8332-8334	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-31	8335-8344	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-32	8345-8346	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-33	8346-8352	unless	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-34	8353-8365	drug-induced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-35	8365-8366	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-36	8366-8367	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-37	8368-8369	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-38	8369-8370	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-39	8371-8378	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-40	8379-8381	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-41	8382-8386	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-42	8387-8394	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-43	8395-8397	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-44	8398-8406	enduring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-45	8407-8413	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-46	8414-8420	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-47	8421-8428	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-48	8429-8430	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-49	8430-8433	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-50	8433-8434	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-51	8434-8435	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-52	8436-8449	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-53	8449-8450	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-54	8451-8458	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-55	8459-8468	affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-56	8469-8477	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-57	8477-8478	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-58	8478-8479	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-59	8480-8481	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-60	8481-8482	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-61	8483-8488	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-62	8489-8496	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-63	8497-8499	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-64	8500-8504	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-65	8505-8516	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-66	8517-8524	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-67	8525-8529	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-68	8529-8530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-69	8531-8533	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-70	8534-8537	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-71	8538-8545	opinion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-72	8546-8548	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-73	8549-8550	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-74	8551-8563	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-75	8563-8564	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-76	8565-8580	contraindicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-77	8581-8594	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-78	8594-8595	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-79	8596-8597	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-80	8597-8598	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-81	8599-8606	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-82	8607-8609	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-83	8610-8618	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-84	8619-8621	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-85	8622-8623	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-86	8624-8635	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-87	8636-8648	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-88	8649-8658	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-89	8659-8663	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-90	8664-8667	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-91	8668-8672	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-92	8673-8683	influenced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-93	8684-8687	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-94	8688-8695	outcome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-95	8696-8698	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-96	8699-8707	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-97	8708-8710	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-98	8711-8714	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-99	8715-8722	results	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-100	8722-8723	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-101	8724-8725	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-102	8725-8726	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-103	8727-8741	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-104	8742-8744	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-105	8745-8751	unable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-106	8752-8754	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-107	8755-8758	lie	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-108	8759-8764	still	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-109	8765-8767	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-110	8768-8771	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-111	8772-8775	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-112	8776-8783	scanner	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-113	8784-8787	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-114	8788-8790	up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-115	8791-8793	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-116	8794-8796	90	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-117	8796-8797	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-118	8797-8800	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-119	8801-8804	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-120	8805-8806	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-121	8806-8807	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-122	8808-8816	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-123	8817-8819	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-124	8820-8821	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-125	8822-8829	cardiac	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-126	8830-8839	pacemaker	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-127	8839-8840	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-128	8841-8846	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-129	8847-8857	electronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-130	8858-8864	device	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-131	8865-8867	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-132	8868-8873	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-133	8874-8877	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-134	8878-8894	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-135	8894-8895	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-136	8896-8905	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-137	8906-8915	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-138	8915-8916	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-139	8917-8919	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-140	8920-8928	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-141	8929-8931	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-142	8932-8933	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-143	8934-8942	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-144	8943-8950	pre-MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-145	8951-8964	questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-146	8964-8965	.	_	

#Text=Secondary or lifetime history of depression or anxiety was permitted in both the ADD and CON groups since these are very common psychiatric disorders.
44-1	8966-8975	Secondary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-2	8976-8978	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-3	8979-8987	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-4	8988-8995	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-5	8996-8998	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-6	8999-9009	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-7	9010-9012	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-8	9013-9020	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-9	9021-9024	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-10	9025-9034	permitted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-11	9035-9037	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-12	9038-9042	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-13	9043-9046	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-14	9047-9050	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[32]	
44-15	9051-9054	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-16	9055-9058	CON	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]	
44-17	9059-9065	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-18	9066-9071	since	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-19	9072-9077	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-20	9078-9081	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-21	9082-9086	very	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-22	9087-9093	common	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-23	9094-9105	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-24	9106-9115	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-25	9115-9116	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=All participants provided written informed consent.
45-1	9117-9120	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-2	9121-9133	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-3	9134-9142	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-4	9143-9150	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-5	9151-9159	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-6	9160-9167	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-7	9167-9168	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	

#Text=The study was conducted in accordance with the Declaration of Helsinki.
46-1	9169-9172	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-2	9173-9178	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-3	9179-9182	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-4	9183-9192	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-5	9193-9195	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-6	9196-9206	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-7	9207-9211	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-8	9212-9215	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-9	9216-9227	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-10	9228-9230	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-11	9231-9239	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-12	9239-9240	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	

#Text=Ethical approval was obtained from West London and Gene Therapy Advisory Committee National Research Ethics Service Committee (11/H0707/9) and relevant research governance and Participant Identification Centre (PIC) approvals obtained.
47-1	9241-9248	Ethical	_	
47-2	9249-9257	approval	_	
47-3	9258-9261	was	_	
47-4	9262-9270	obtained	_	
47-5	9271-9275	from	_	
47-6	9276-9280	West	_	
47-7	9281-9287	London	_	
47-8	9288-9291	and	_	
47-9	9292-9296	Gene	_	
47-10	9297-9304	Therapy	_	
47-11	9305-9313	Advisory	_	
47-12	9314-9323	Committee	_	
47-13	9324-9332	National	_	
47-14	9333-9341	Research	_	
47-15	9342-9348	Ethics	_	
47-16	9349-9356	Service	_	
47-17	9357-9366	Committee	_	
47-18	9367-9368	(	_	
47-19	9368-9370	11	_	
47-20	9370-9371	/	_	
47-21	9371-9376	H0707	_	
47-22	9376-9377	/	_	
47-23	9377-9378	9	_	
47-24	9378-9379	)	_	
47-25	9380-9383	and	_	
47-26	9384-9392	relevant	_	
47-27	9393-9401	research	_	
47-28	9402-9412	governance	_	
47-29	9413-9416	and	_	
47-30	9417-9428	Participant	_	
47-31	9429-9443	Identification	_	
47-32	9444-9450	Centre	_	
47-33	9451-9452	(	_	
47-34	9452-9455	PIC	_	
47-35	9455-9456	)	_	
47-36	9457-9466	approvals	_	
47-37	9467-9475	obtained	_	
47-38	9475-9476	.	_	

#Text=Monetary incentive delay task (MID)
#Text=We used a “monetary incentive delay task” (MID), which was based on that originally employed by Knutson, and which we have used to already publish data from the ICCAM platform.
48-1	9477-9485	Monetary	_	
48-2	9486-9495	incentive	_	
48-3	9496-9501	delay	_	
48-4	9502-9506	task	_	
48-5	9507-9508	(	_	
48-6	9508-9511	MID	_	
48-7	9511-9512	)	_	
48-8	9513-9515	We	_	
48-9	9516-9520	used	_	
48-10	9521-9522	a	_	
48-11	9523-9524	“	_	
48-12	9524-9532	monetary	_	
48-13	9533-9542	incentive	_	
48-14	9543-9548	delay	_	
48-15	9549-9553	task	_	
48-16	9553-9554	”	_	
48-17	9555-9556	(	_	
48-18	9556-9559	MID	_	
48-19	9559-9560	)	_	
48-20	9560-9561	,	_	
48-21	9562-9567	which	_	
48-22	9568-9571	was	_	
48-23	9572-9577	based	_	
48-24	9578-9580	on	_	
48-25	9581-9585	that	_	
48-26	9586-9596	originally	_	
48-27	9597-9605	employed	_	
48-28	9606-9608	by	_	
48-29	9609-9616	Knutson	_	
48-30	9616-9617	,	_	
48-31	9618-9621	and	_	
48-32	9622-9627	which	_	
48-33	9628-9630	we	_	
48-34	9631-9635	have	_	
48-35	9636-9640	used	_	
48-36	9641-9643	to	_	
48-37	9644-9651	already	_	
48-38	9652-9659	publish	_	
48-39	9660-9664	data	_	
48-40	9665-9669	from	_	
48-41	9670-9673	the	_	
48-42	9674-9679	ICCAM	_	
48-43	9680-9688	platform	_	
48-44	9688-9689	.	_	

#Text=At the beginning of each trial, participants viewed one of three symbols (a cue) that indicated the potential to gain fifty pence (square containing an ascending arrow), lose fifty pence (square containing a descending arrow) or experience no financial outcome (square containing a horizontal line - here referred to as a neutral trial).
49-1	9690-9692	At	_	
49-2	9693-9696	the	_	
49-3	9697-9706	beginning	_	
49-4	9707-9709	of	_	
49-5	9710-9714	each	_	
49-6	9715-9720	trial	_	
49-7	9720-9721	,	_	
49-8	9722-9734	participants	_	
49-9	9735-9741	viewed	_	
49-10	9742-9745	one	_	
49-11	9746-9748	of	_	
49-12	9749-9754	three	_	
49-13	9755-9762	symbols	_	
49-14	9763-9764	(	_	
49-15	9764-9765	a	_	
49-16	9766-9769	cue	_	
49-17	9769-9770	)	_	
49-18	9771-9775	that	_	
49-19	9776-9785	indicated	_	
49-20	9786-9789	the	_	
49-21	9790-9799	potential	_	
49-22	9800-9802	to	_	
49-23	9803-9807	gain	_	
49-24	9808-9813	fifty	_	
49-25	9814-9819	pence	_	
49-26	9820-9821	(	_	
49-27	9821-9827	square	_	
49-28	9828-9838	containing	_	
49-29	9839-9841	an	_	
49-30	9842-9851	ascending	_	
49-31	9852-9857	arrow	_	
49-32	9857-9858	)	_	
49-33	9858-9859	,	_	
49-34	9860-9864	lose	_	
49-35	9865-9870	fifty	_	
49-36	9871-9876	pence	_	
49-37	9877-9878	(	_	
49-38	9878-9884	square	_	
49-39	9885-9895	containing	_	
49-40	9896-9897	a	_	
49-41	9898-9908	descending	_	
49-42	9909-9914	arrow	_	
49-43	9914-9915	)	_	
49-44	9916-9918	or	_	
49-45	9919-9929	experience	_	
49-46	9930-9932	no	_	
49-47	9933-9942	financial	_	
49-48	9943-9950	outcome	_	
49-49	9951-9952	(	_	
49-50	9952-9958	square	_	
49-51	9959-9969	containing	_	
49-52	9970-9971	a	_	
49-53	9972-9982	horizontal	_	
49-54	9983-9987	line	_	
49-55	9988-9989	-	_	
49-56	9990-9994	here	_	
49-57	9995-10003	referred	_	
49-58	10004-10006	to	_	
49-59	10007-10009	as	_	
49-60	10010-10011	a	_	
49-61	10012-10019	neutral	_	
49-62	10020-10025	trial	_	
49-63	10025-10026	)	_	
49-64	10026-10027	.	_	

#Text=Each cue was presented for one second, with a variable duration (2–4 s) for the subsequent anticipation period.
50-1	10028-10032	Each	_	
50-2	10033-10036	cue	_	
50-3	10037-10040	was	_	
50-4	10041-10050	presented	_	
50-5	10051-10054	for	_	
50-6	10055-10058	one	_	
50-7	10059-10065	second	_	
50-8	10065-10066	,	_	
50-9	10067-10071	with	_	
50-10	10072-10073	a	_	
50-11	10074-10082	variable	_	
50-12	10083-10091	duration	_	
50-13	10092-10093	(	_	
50-14	10093-10094	2	_	
50-15	10094-10095	–	_	
50-16	10095-10096	4	_	
50-17	10096-10097	 	_	
50-18	10097-10098	s	_	
50-19	10098-10099	)	_	
50-20	10100-10103	for	_	
50-21	10104-10107	the	_	
50-22	10108-10118	subsequent	_	
50-23	10119-10131	anticipation	_	
50-24	10132-10138	period	_	
50-25	10138-10139	.	_	

#Text=Following the anticipation period, participants made a button press response upon the presentation of a visual target (star located within a circle).
51-1	10140-10149	Following	_	
51-2	10150-10153	the	_	
51-3	10154-10166	anticipation	_	
51-4	10167-10173	period	_	
51-5	10173-10174	,	_	
51-6	10175-10187	participants	_	
51-7	10188-10192	made	_	
51-8	10193-10194	a	_	
51-9	10195-10201	button	_	
51-10	10202-10207	press	_	
51-11	10208-10216	response	_	
51-12	10217-10221	upon	_	
51-13	10222-10225	the	_	
51-14	10226-10238	presentation	_	
51-15	10239-10241	of	_	
51-16	10242-10243	a	_	
51-17	10244-10250	visual	_	
51-18	10251-10257	target	_	
51-19	10258-10259	(	_	
51-20	10259-10263	star	_	
51-21	10264-10271	located	_	
51-22	10272-10278	within	_	
51-23	10279-10280	a	_	
51-24	10281-10287	circle	_	
51-25	10287-10288	)	_	
51-26	10288-10289	.	_	

#Text=Following their response to the visual target, participants received feedback (1.5 s) as to whether they were successful (“Hit”) or unsuccessful (“Miss”) on that trial and saw a running total of their winnings up to that point in the task.
52-1	10290-10299	Following	_	
52-2	10300-10305	their	_	
52-3	10306-10314	response	_	
52-4	10315-10317	to	_	
52-5	10318-10321	the	_	
52-6	10322-10328	visual	_	
52-7	10329-10335	target	_	
52-8	10335-10336	,	_	
52-9	10337-10349	participants	_	
52-10	10350-10358	received	_	
52-11	10359-10367	feedback	_	
52-12	10368-10369	(	_	
52-13	10369-10372	1.5	_	
52-14	10372-10373	 	_	
52-15	10373-10374	s	_	
52-16	10374-10375	)	_	
52-17	10376-10378	as	_	
52-18	10379-10381	to	_	
52-19	10382-10389	whether	_	
52-20	10390-10394	they	_	
52-21	10395-10399	were	_	
52-22	10400-10410	successful	_	
52-23	10411-10412	(	_	
52-24	10412-10413	“	_	
52-25	10413-10416	Hit	_	
52-26	10416-10417	”	_	
52-27	10417-10418	)	_	
52-28	10419-10421	or	_	
52-29	10422-10434	unsuccessful	_	
52-30	10435-10436	(	_	
52-31	10436-10437	“	_	
52-32	10437-10441	Miss	_	
52-33	10441-10442	”	_	
52-34	10442-10443	)	_	
52-35	10444-10446	on	_	
52-36	10447-10451	that	_	
52-37	10452-10457	trial	_	
52-38	10458-10461	and	_	
52-39	10462-10465	saw	_	
52-40	10466-10467	a	_	
52-41	10468-10475	running	_	
52-42	10476-10481	total	_	
52-43	10482-10484	of	_	
52-44	10485-10490	their	_	
52-45	10491-10499	winnings	_	
52-46	10500-10502	up	_	
52-47	10503-10505	to	_	
52-48	10506-10510	that	_	
52-49	10511-10516	point	_	
52-50	10517-10519	in	_	
52-51	10520-10523	the	_	
52-52	10524-10528	task	_	
52-53	10528-10529	.	_	

#Text=Following feedback, there was an end fixation period (3–5 s) before the commencement of the next trial.
53-1	10530-10539	Following	_	
53-2	10540-10548	feedback	_	
53-3	10548-10549	,	_	
53-4	10550-10555	there	_	
53-5	10556-10559	was	_	
53-6	10560-10562	an	_	
53-7	10563-10566	end	_	
53-8	10567-10575	fixation	_	
53-9	10576-10582	period	_	
53-10	10583-10584	(	_	
53-11	10584-10585	3	_	
53-12	10585-10586	–	_	
53-13	10586-10587	5	_	
53-14	10587-10588	 	_	
53-15	10588-10589	s	_	
53-16	10589-10590	)	_	
53-17	10591-10597	before	_	
53-18	10598-10601	the	_	
53-19	10602-10614	commencement	_	
53-20	10615-10617	of	_	
53-21	10618-10621	the	_	
53-22	10622-10626	next	_	
53-23	10627-10632	trial	_	
53-24	10632-10633	.	_	

#Text=Because the primary objective of ICCAM was to examine the neural correlates of reward anticipation, we chose to use a smaller number of loss trials in order to amplify the incentive salience of the gain trials during the task.
54-1	10634-10641	Because	_	
54-2	10642-10645	the	_	
54-3	10646-10653	primary	_	
54-4	10654-10663	objective	_	
54-5	10664-10666	of	_	
54-6	10667-10672	ICCAM	_	
54-7	10673-10676	was	_	
54-8	10677-10679	to	_	
54-9	10680-10687	examine	_	
54-10	10688-10691	the	_	
54-11	10692-10698	neural	_	
54-12	10699-10709	correlates	_	
54-13	10710-10712	of	_	
54-14	10713-10719	reward	_	
54-15	10720-10732	anticipation	_	
54-16	10732-10733	,	_	
54-17	10734-10736	we	_	
54-18	10737-10742	chose	_	
54-19	10743-10745	to	_	
54-20	10746-10749	use	_	
54-21	10750-10751	a	_	
54-22	10752-10759	smaller	_	
54-23	10760-10766	number	_	
54-24	10767-10769	of	_	
54-25	10770-10774	loss	_	
54-26	10775-10781	trials	_	
54-27	10782-10784	in	_	
54-28	10785-10790	order	_	
54-29	10791-10793	to	_	
54-30	10794-10801	amplify	_	
54-31	10802-10805	the	_	
54-32	10806-10815	incentive	_	
54-33	10816-10824	salience	_	
54-34	10825-10827	of	_	
54-35	10828-10831	the	_	
54-36	10832-10836	gain	_	
54-37	10837-10843	trials	_	
54-38	10844-10850	during	_	
54-39	10851-10854	the	_	
54-40	10855-10859	task	_	
54-41	10859-10860	.	_	

#Text=Consequently, there was a total of 18 gain, 6 lose and 18 neutral trials on each run of the task.
55-1	10861-10873	Consequently	_	
55-2	10873-10874	,	_	
55-3	10875-10880	there	_	
55-4	10881-10884	was	_	
55-5	10885-10886	a	_	
55-6	10887-10892	total	_	
55-7	10893-10895	of	_	
55-8	10896-10898	18	_	
55-9	10899-10903	gain	_	
55-10	10903-10904	,	_	
55-11	10905-10906	6	_	
55-12	10907-10911	lose	_	
55-13	10912-10915	and	_	
55-14	10916-10918	18	_	
55-15	10919-10926	neutral	_	
55-16	10927-10933	trials	_	
55-17	10934-10936	on	_	
55-18	10937-10941	each	_	
55-19	10942-10945	run	_	
55-20	10946-10948	of	_	
55-21	10949-10952	the	_	
55-22	10953-10957	task	_	
55-23	10957-10958	.	_	

#Text=The MID task was tailored to adapt to the visual target reaction time of each participant by using a staircase algorithm, such that the presentation of the visual target became shorter as performance improved during the experiment.
56-1	10959-10962	The	_	
56-2	10963-10966	MID	_	
56-3	10967-10971	task	_	
56-4	10972-10975	was	_	
56-5	10976-10984	tailored	_	
56-6	10985-10987	to	_	
56-7	10988-10993	adapt	_	
56-8	10994-10996	to	_	
56-9	10997-11000	the	_	
56-10	11001-11007	visual	_	
56-11	11008-11014	target	_	
56-12	11015-11023	reaction	_	
56-13	11024-11028	time	_	
56-14	11029-11031	of	_	
56-15	11032-11036	each	_	
56-16	11037-11048	participant	_	
56-17	11049-11051	by	_	
56-18	11052-11057	using	_	
56-19	11058-11059	a	_	
56-20	11060-11069	staircase	_	
56-21	11070-11079	algorithm	_	
56-22	11079-11080	,	_	
56-23	11081-11085	such	_	
56-24	11086-11090	that	_	
56-25	11091-11094	the	_	
56-26	11095-11107	presentation	_	
56-27	11108-11110	of	_	
56-28	11111-11114	the	_	
56-29	11115-11121	visual	_	
56-30	11122-11128	target	_	
56-31	11129-11135	became	_	
56-32	11136-11143	shorter	_	
56-33	11144-11146	as	_	
56-34	11147-11158	performance	_	
56-35	11159-11167	improved	_	
56-36	11168-11174	during	_	
56-37	11175-11178	the	_	
56-38	11179-11189	experiment	_	
56-39	11189-11190	.	_	

#Text=This enabled us to set a limit on the success rate of each participant (∼66%), which additionally served to incentivize participants to engage in the task.
57-1	11191-11195	This	_	
57-2	11196-11203	enabled	_	
57-3	11204-11206	us	_	
57-4	11207-11209	to	_	
57-5	11210-11213	set	_	
57-6	11214-11215	a	_	
57-7	11216-11221	limit	_	
57-8	11222-11224	on	_	
57-9	11225-11228	the	_	
57-10	11229-11236	success	_	
57-11	11237-11241	rate	_	
57-12	11242-11244	of	_	
57-13	11245-11249	each	_	
57-14	11250-11261	participant	_	
57-15	11262-11263	(	_	
57-16	11263-11264	∼	_	
57-17	11264-11267	66%	_	
57-18	11267-11268	)	_	
57-19	11268-11269	,	_	
57-20	11270-11275	which	_	
57-21	11276-11288	additionally	_	
57-22	11289-11295	served	_	
57-23	11296-11298	to	_	
57-24	11299-11310	incentivize	_	
57-25	11311-11323	participants	_	
57-26	11324-11326	to	_	
57-27	11327-11333	engage	_	
57-28	11334-11336	in	_	
57-29	11337-11340	the	_	
57-30	11341-11345	task	_	
57-31	11345-11346	.	_	

#Text=Participants were instructed to maximize their winnings and were told they would receive them at the end of the study.
58-1	11347-11359	Participants	_	
58-2	11360-11364	were	_	
58-3	11365-11375	instructed	_	
58-4	11376-11378	to	_	
58-5	11379-11387	maximize	_	
58-6	11388-11393	their	_	
58-7	11394-11402	winnings	_	
58-8	11403-11406	and	_	
58-9	11407-11411	were	_	
58-10	11412-11416	told	_	
58-11	11417-11421	they	_	
58-12	11422-11427	would	_	
58-13	11428-11435	receive	_	
58-14	11436-11440	them	_	
58-15	11441-11443	at	_	
58-16	11444-11447	the	_	
58-17	11448-11451	end	_	
58-18	11452-11454	of	_	
58-19	11455-11458	the	_	
58-20	11459-11464	study	_	
58-21	11464-11465	.	_	

#Text=Dependent measures were accuracy (percentage) and mean reaction time (milliseconds) to the visual target on each of the gain, lose and neutral trials, and the amount won (£) on the task.
59-1	11466-11475	Dependent	_	
59-2	11476-11484	measures	_	
59-3	11485-11489	were	_	
59-4	11490-11498	accuracy	_	
59-5	11499-11500	(	_	
59-6	11500-11510	percentage	_	
59-7	11510-11511	)	_	
59-8	11512-11515	and	_	
59-9	11516-11520	mean	_	
59-10	11521-11529	reaction	_	
59-11	11530-11534	time	_	
59-12	11535-11536	(	_	
59-13	11536-11548	milliseconds	_	
59-14	11548-11549	)	_	
59-15	11550-11552	to	_	
59-16	11553-11556	the	_	
59-17	11557-11563	visual	_	
59-18	11564-11570	target	_	
59-19	11571-11573	on	_	
59-20	11574-11578	each	_	
59-21	11579-11581	of	_	
59-22	11582-11585	the	_	
59-23	11586-11590	gain	_	
59-24	11590-11591	,	_	
59-25	11592-11596	lose	_	
59-26	11597-11600	and	_	
59-27	11601-11608	neutral	_	
59-28	11609-11615	trials	_	
59-29	11615-11616	,	_	
59-30	11617-11620	and	_	
59-31	11621-11624	the	_	
59-32	11625-11631	amount	_	
59-33	11632-11635	won	_	
59-34	11636-11637	(	_	
59-35	11637-11638	£	_	
59-36	11638-11639	)	_	
59-37	11640-11642	on	_	
59-38	11643-11646	the	_	
59-39	11647-11651	task	_	
59-40	11651-11652	.	_	

#Text=Participants completed two runs of the task (432 s each) during scanning.
60-1	11653-11665	Participants	_	
60-2	11666-11675	completed	_	
60-3	11676-11679	two	_	
60-4	11680-11684	runs	_	
60-5	11685-11687	of	_	
60-6	11688-11691	the	_	
60-7	11692-11696	task	_	
60-8	11697-11698	(	_	
60-9	11698-11701	432	_	
60-10	11701-11702	 	_	
60-11	11702-11703	s	_	
60-12	11704-11708	each	_	
60-13	11708-11709	)	_	
60-14	11710-11716	during	_	
60-15	11717-11725	scanning	_	
60-16	11725-11726	.	_	

#Text=The task was programmed using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).
61-1	11727-11730	The	_	
61-2	11731-11735	task	_	
61-3	11736-11739	was	_	
61-4	11740-11750	programmed	_	
61-5	11751-11756	using	_	
61-6	11757-11764	E-Prime	_	
61-7	11765-11772	version	_	
61-8	11773-11776	2.0	_	
61-9	11777-11778	(	_	
61-10	11778-11788	Psychology	_	
61-11	11789-11797	Software	_	
61-12	11798-11803	Tools	_	
61-13	11803-11804	,	_	
61-14	11805-11815	Pittsburgh	_	
61-15	11815-11816	,	_	
61-16	11817-11820	USA	_	
61-17	11820-11821	)	_	
61-18	11821-11822	.	_	

#Text=Statistics
#Text=Group demographics were compared using simple independent samples t-test analyses.
62-1	11823-11833	Statistics	_	
62-2	11834-11839	Group	_	
62-3	11840-11852	demographics	_	
62-4	11853-11857	were	_	
62-5	11858-11866	compared	_	
62-6	11867-11872	using	_	
62-7	11873-11879	simple	_	
62-8	11880-11891	independent	_	
62-9	11892-11899	samples	_	
62-10	11900-11906	t-test	_	
62-11	11907-11915	analyses	_	
62-12	11915-11916	.	_	

#Text=For analyses conducted on MID performance, two (Group: CON vs.
63-1	11917-11920	For	_	
63-2	11921-11929	analyses	_	
63-3	11930-11939	conducted	_	
63-4	11940-11942	on	_	
63-5	11943-11946	MID	_	
63-6	11947-11958	performance	_	
63-7	11958-11959	,	_	
63-8	11960-11963	two	_	
63-9	11964-11965	(	_	
63-10	11965-11970	Group	_	
63-11	11970-11971	:	_	
63-12	11972-11975	CON	_	
63-13	11976-11978	vs	_	
63-14	11978-11979	.	_	

#Text=ADD) by two (Condition: Gain vs.
64-1	11980-11983	ADD	_	
64-2	11983-11984	)	_	
64-3	11985-11987	by	_	
64-4	11988-11991	two	_	
64-5	11992-11993	(	_	
64-6	11993-12002	Condition	_	
64-7	12002-12003	:	_	
64-8	12004-12008	Gain	_	
64-9	12009-12011	vs	_	
64-10	12011-12012	.	_	

#Text=Neutral) analyses of variance were conducted.
65-1	12013-12020	Neutral	_	
65-2	12020-12021	)	_	
65-3	12022-12030	analyses	_	
65-4	12031-12033	of	_	
65-5	12034-12042	variance	_	
65-6	12043-12047	were	_	
65-7	12048-12057	conducted	_	
65-8	12057-12058	.	_	

#Text=The CON and ADD groups were also compared on the lose accuracy and lose reaction time performance measures, as well as the amount of money won (£), using analyses of variance.
66-1	12059-12062	The	_	
66-2	12063-12066	CON	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
66-3	12067-12070	and	_	
66-4	12071-12074	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[36]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[37]	
66-5	12075-12081	groups	_	
66-6	12082-12086	were	_	
66-7	12087-12091	also	_	
66-8	12092-12100	compared	_	
66-9	12101-12103	on	_	
66-10	12104-12107	the	_	
66-11	12108-12112	lose	_	
66-12	12113-12121	accuracy	_	
66-13	12122-12125	and	_	
66-14	12126-12130	lose	_	
66-15	12131-12139	reaction	_	
66-16	12140-12144	time	_	
66-17	12145-12156	performance	_	
66-18	12157-12165	measures	_	
66-19	12165-12166	,	_	
66-20	12167-12169	as	_	
66-21	12170-12174	well	_	
66-22	12175-12177	as	_	
66-23	12178-12181	the	_	
66-24	12182-12188	amount	_	
66-25	12189-12191	of	_	
66-26	12192-12197	money	_	
66-27	12198-12201	won	_	
66-28	12202-12203	(	_	
66-29	12203-12204	£	_	
66-30	12204-12205	)	_	
66-31	12205-12206	,	_	
66-32	12207-12212	using	_	
66-33	12213-12221	analyses	_	
66-34	12222-12224	of	_	
66-35	12225-12233	variance	_	
66-36	12233-12234	.	_	

#Text=These analyses were conducted controlling for study site.
67-1	12235-12240	These	_	
67-2	12241-12249	analyses	_	
67-3	12250-12254	were	_	
67-4	12255-12264	conducted	_	
67-5	12265-12276	controlling	_	
67-6	12277-12280	for	_	
67-7	12281-12286	study	_	
67-8	12287-12291	site	_	
67-9	12291-12292	.	_	

#Text=For the graph measures (see below) we conducted two (Group: CON vs.
68-1	12293-12296	For	_	
68-2	12297-12300	the	_	
68-3	12301-12306	graph	_	
68-4	12307-12315	measures	_	
68-5	12316-12317	(	_	
68-6	12317-12320	see	_	
68-7	12321-12326	below	_	
68-8	12326-12327	)	_	
68-9	12328-12330	we	_	
68-10	12331-12340	conducted	_	
68-11	12341-12344	two	_	
68-12	12345-12346	(	_	
68-13	12346-12351	Group	_	
68-14	12351-12352	:	_	
68-15	12353-12356	CON	_	
68-16	12357-12359	vs	_	
68-17	12359-12360	.	_	

#Text=ADD) by five (1 ⩽ K ⩽ 5) analyses of variance, while also controlling for study site.
69-1	12361-12364	ADD	_	
69-2	12364-12365	)	_	
69-3	12366-12368	by	_	
69-4	12369-12373	five	_	
69-5	12374-12375	(	_	
69-6	12375-12376	1	_	
69-7	12376-12377	 	_	
69-8	12377-12378	⩽	_	
69-9	12378-12379	 	_	
69-10	12379-12380	K	_	
69-11	12380-12381	 	_	
69-12	12381-12382	⩽	_	
69-13	12382-12383	 	_	
69-14	12383-12384	5	_	
69-15	12384-12385	)	_	
69-16	12386-12394	analyses	_	
69-17	12395-12397	of	_	
69-18	12398-12406	variance	_	
69-19	12406-12407	,	_	
69-20	12408-12413	while	_	
69-21	12414-12418	also	_	
69-22	12419-12430	controlling	_	
69-23	12431-12434	for	_	
69-24	12435-12440	study	_	
69-25	12441-12445	site	_	
69-26	12445-12446	.	_	

#Text=All these analyses were conducted using permutation testing (5000 iterations) in the R statistical software package (www.R-project.org).
70-1	12447-12450	All	_	
70-2	12451-12456	these	_	
70-3	12457-12465	analyses	_	
70-4	12466-12470	were	_	
70-5	12471-12480	conducted	_	
70-6	12481-12486	using	_	
70-7	12487-12498	permutation	_	
70-8	12499-12506	testing	_	
70-9	12507-12508	(	_	
70-10	12508-12512	5000	_	
70-11	12513-12523	iterations	_	
70-12	12523-12524	)	_	
70-13	12525-12527	in	_	
70-14	12528-12531	the	_	
70-15	12532-12533	R	_	
70-16	12534-12545	statistical	_	
70-17	12546-12554	software	_	
70-18	12555-12562	package	_	
70-19	12563-12564	(	_	
70-20	12564-12581	www.R-project.org	_	
70-21	12581-12582	)	_	
70-22	12582-12583	.	_	

#Text=Functional MRI (fMRI) Data acquisition
#Text=The ICCAM platform was designed to allow the rapid testing across sites of multiple compounds relevant to addiction treatment.
71-1	12584-12594	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-2	12595-12598	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-3	12599-12600	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-4	12600-12604	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-5	12604-12605	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-6	12606-12610	Data	_	
71-7	12611-12622	acquisition	_	
71-8	12623-12626	The	_	
71-9	12627-12632	ICCAM	_	
71-10	12633-12641	platform	_	
71-11	12642-12645	was	_	
71-12	12646-12654	designed	_	
71-13	12655-12657	to	_	
71-14	12658-12663	allow	_	
71-15	12664-12667	the	_	
71-16	12668-12673	rapid	_	
71-17	12674-12681	testing	_	
71-18	12682-12688	across	_	
71-19	12689-12694	sites	_	
71-20	12695-12697	of	_	
71-21	12698-12706	multiple	_	
71-22	12707-12716	compounds	_	
71-23	12717-12725	relevant	_	
71-24	12726-12728	to	_	
71-25	12729-12738	addiction	_	
71-26	12739-12748	treatment	_	
71-27	12748-12749	.	_	

#Text=Imaging at multiple sites in parallel on the ICCAM platform accelerated study completion, through the sharing of expertise, infrastructure and capacity. 
72-1	12750-12757	Imaging	_	
72-2	12758-12760	at	_	
72-3	12761-12769	multiple	_	
72-4	12770-12775	sites	_	
72-5	12776-12778	in	_	
72-6	12779-12787	parallel	_	
72-7	12788-12790	on	_	
72-8	12791-12794	the	_	
72-9	12795-12800	ICCAM	_	
72-10	12801-12809	platform	_	
72-11	12810-12821	accelerated	_	
72-12	12822-12827	study	_	
72-13	12828-12838	completion	_	
72-14	12838-12839	,	_	
72-15	12840-12847	through	_	
72-16	12848-12851	the	_	
72-17	12852-12859	sharing	_	
72-18	12860-12862	of	_	
72-19	12863-12872	expertise	_	
72-20	12872-12873	,	_	
72-21	12874-12888	infrastructure	_	
72-22	12889-12892	and	_	
72-23	12893-12901	capacity	_	
72-24	12901-12902	.	_	
72-25	12902-12903	 	_	

#Text=For a more comprehensive description of data acquisition across the three sites on ICCAM, please see McGonigle et al.
73-1	12903-12906	For	_	
73-2	12907-12908	a	_	
73-3	12909-12913	more	_	
73-4	12914-12927	comprehensive	_	
73-5	12928-12939	description	_	
73-6	12940-12942	of	_	
73-7	12943-12947	data	_	
73-8	12948-12959	acquisition	_	
73-9	12960-12966	across	_	
73-10	12967-12970	the	_	
73-11	12971-12976	three	_	
73-12	12977-12982	sites	_	
73-13	12983-12985	on	_	
73-14	12986-12991	ICCAM	_	
73-15	12991-12992	,	_	
73-16	12993-12999	please	_	
73-17	13000-13003	see	_	
73-18	13004-13013	McGonigle	_	
73-19	13014-13016	et	_	
73-20	13017-13019	al	_	
73-21	13019-13020	.	_	

#Text=Briefly, all centres operated MRI machines with a main magnetic field of 3 T (T).
74-1	13021-13028	Briefly	_	
74-2	13028-13029	,	_	
74-3	13030-13033	all	_	
74-4	13034-13041	centres	_	
74-5	13042-13050	operated	_	
74-6	13051-13054	MRI	_	
74-7	13055-13063	machines	_	
74-8	13064-13068	with	_	
74-9	13069-13070	a	_	
74-10	13071-13075	main	_	
74-11	13076-13084	magnetic	_	
74-12	13085-13090	field	_	
74-13	13091-13093	of	_	
74-14	13094-13095	3	_	
74-15	13095-13096	 	_	
74-16	13096-13097	T	_	
74-17	13098-13099	(	_	
74-18	13099-13100	T	_	
74-19	13100-13101	)	_	
74-20	13101-13102	.	_	

#Text=Centres in London and Cambridge operated nominally identical 3 T Siemens Tim Trio systems running the syngo MR B17 software with a Siemens 32 channel receive-only phased-array head coil.
75-1	13103-13110	Centres	_	
75-2	13111-13113	in	_	
75-3	13114-13120	London	_	
75-4	13121-13124	and	_	
75-5	13125-13134	Cambridge	_	
75-6	13135-13143	operated	_	
75-7	13144-13153	nominally	_	
75-8	13154-13163	identical	_	
75-9	13164-13165	3	_	
75-10	13165-13166	 	_	
75-11	13166-13167	T	_	
75-12	13168-13175	Siemens	_	
75-13	13176-13179	Tim	_	
75-14	13180-13184	Trio	_	
75-15	13185-13192	systems	_	
75-16	13193-13200	running	_	
75-17	13201-13204	the	_	
75-18	13205-13210	syngo	_	
75-19	13211-13213	MR	_	
75-20	13214-13217	B17	_	
75-21	13218-13226	software	_	
75-22	13227-13231	with	_	
75-23	13232-13233	a	_	
75-24	13234-13241	Siemens	_	
75-25	13242-13244	32	_	
75-26	13245-13252	channel	_	
75-27	13253-13265	receive-only	_	
75-28	13266-13278	phased-array	_	
75-29	13279-13283	head	_	
75-30	13284-13288	coil	_	
75-31	13288-13289	.	_	

#Text=The Manchester centre operated a 3 T Philips Achieva running version 2.6.3.5 software and an 8 element SENSE head coil.
76-1	13290-13293	The	_	
76-2	13294-13304	Manchester	_	
76-3	13305-13311	centre	_	
76-4	13312-13320	operated	_	
76-5	13321-13322	a	_	
76-6	13323-13324	3	_	
76-7	13324-13325	 	_	
76-8	13325-13326	T	_	
76-9	13327-13334	Philips	_	
76-10	13335-13342	Achieva	_	
76-11	13343-13350	running	_	
76-12	13351-13358	version	_	
76-13	13359-13366	2.6.3.5	_	
76-14	13367-13375	software	_	
76-15	13376-13379	and	_	
76-16	13380-13382	an	_	
76-17	13383-13384	8	_	
76-18	13385-13392	element	_	
76-19	13393-13398	SENSE	_	
76-20	13399-13403	head	_	
76-21	13404-13408	coil	_	
76-22	13408-13409	.	_	

#Text=For anatomical images, 160 high-resolution T1-weighted anatomic MPRAGE axial images (FOV 256 mm, thickness 1.0 mm, voxel size 1.0 × 1.0 × 1.0) were acquired (total duration 303 s).
77-1	13410-13413	For	_	
77-2	13414-13424	anatomical	_	
77-3	13425-13431	images	_	
77-4	13431-13432	,	_	
77-5	13433-13436	160	_	
77-6	13437-13452	high-resolution	_	
77-7	13453-13455	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
77-8	13455-13456	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
77-9	13456-13464	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
77-10	13465-13473	anatomic	_	
77-11	13474-13480	MPRAGE	_	
77-12	13481-13486	axial	_	
77-13	13487-13493	images	_	
77-14	13494-13495	(	_	
77-15	13495-13498	FOV	_	
77-16	13499-13502	256	_	
77-17	13502-13503	 	_	
77-18	13503-13505	mm	_	
77-19	13505-13506	,	_	
77-20	13507-13516	thickness	_	
77-21	13517-13520	1.0	_	
77-22	13520-13521	 	_	
77-23	13521-13523	mm	_	
77-24	13523-13524	,	_	
77-25	13525-13530	voxel	_	
77-26	13531-13535	size	_	
77-27	13536-13539	1.0	_	
77-28	13539-13540	 	_	
77-29	13540-13541	×	_	
77-30	13541-13542	 	_	
77-31	13542-13545	1.0	_	
77-32	13545-13546	 	_	
77-33	13546-13547	×	_	
77-34	13547-13548	 	_	
77-35	13548-13551	1.0	_	
77-36	13551-13552	)	_	
77-37	13553-13557	were	_	
77-38	13558-13566	acquired	_	
77-39	13567-13568	(	_	
77-40	13568-13573	total	_	
77-41	13574-13582	duration	_	
77-42	13583-13586	303	_	
77-43	13586-13587	 	_	
77-44	13587-13588	s	_	
77-45	13588-13589	)	_	
77-46	13589-13590	.	_	

#Text=Functional data were acquired using a T2* weighted echo-planar imaging sequence collecting 36 non-contiguous (0% gap) 3.0 mm axial slices covering the entire brain (TE = 31 ms, TR = 2000 ms, FOV 225 mm, 64 × 64 mm matrix size in Fourier space).
78-1	13591-13601	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
78-2	13602-13606	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
78-3	13607-13611	were	_	
78-4	13612-13620	acquired	_	
78-5	13621-13626	using	_	
78-6	13627-13628	a	_	
78-7	13629-13631	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[41]	
78-8	13631-13632	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[41]	
78-9	13633-13641	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[41]	
78-10	13642-13653	echo-planar	_	
78-11	13654-13661	imaging	_	
78-12	13662-13670	sequence	_	
78-13	13671-13681	collecting	_	
78-14	13682-13684	36	_	
78-15	13685-13699	non-contiguous	_	
78-16	13700-13701	(	_	
78-17	13701-13703	0%	_	
78-18	13704-13707	gap	_	
78-19	13707-13708	)	_	
78-20	13709-13712	3.0	_	
78-21	13712-13713	 	_	
78-22	13713-13715	mm	_	
78-23	13716-13721	axial	_	
78-24	13722-13728	slices	_	
78-25	13729-13737	covering	_	
78-26	13738-13741	the	_	
78-27	13742-13748	entire	_	
78-28	13749-13754	brain	_	
78-29	13755-13756	(	_	
78-30	13756-13758	TE	_	
78-31	13758-13759	 	_	
78-32	13759-13760	=	_	
78-33	13760-13761	 	_	
78-34	13761-13763	31	_	
78-35	13763-13764	 	_	
78-36	13764-13766	ms	_	
78-37	13766-13767	,	_	
78-38	13768-13770	TR	_	
78-39	13770-13771	 	_	
78-40	13771-13772	=	_	
78-41	13772-13773	 	_	
78-42	13773-13777	2000	_	
78-43	13777-13778	 	_	
78-44	13778-13780	ms	_	
78-45	13780-13781	,	_	
78-46	13782-13785	FOV	_	
78-47	13786-13789	225	_	
78-48	13789-13790	 	_	
78-49	13790-13792	mm	_	
78-50	13792-13793	,	_	
78-51	13794-13796	64	_	
78-52	13796-13797	 	_	
78-53	13797-13798	×	_	
78-54	13798-13799	 	_	
78-55	13799-13801	64	_	
78-56	13801-13802	 	_	
78-57	13802-13804	mm	_	
78-58	13805-13811	matrix	_	
78-59	13812-13816	size	_	
78-60	13817-13819	in	_	
78-61	13820-13827	Fourier	_	
78-62	13828-13833	space	_	
78-63	13833-13834	)	_	
78-64	13834-13835	.	_	

#Text=Each run of the MID task produced a total of 216 volumes of functional MRI data.
#Text=fMRI Data analyses
#Text=Data pre-processing and statistical analysis were conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl).
79-1	13836-13840	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-2	13841-13844	run	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-3	13845-13847	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-4	13848-13851	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-5	13852-13855	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-6	13856-13860	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-7	13861-13869	produced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-8	13870-13871	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-9	13872-13877	total	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-10	13878-13880	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-11	13881-13884	216	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-12	13885-13892	volumes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-13	13893-13895	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-14	13896-13906	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[43]	
79-15	13907-13910	MRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[43]	
79-16	13911-13915	data	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[43]	
79-17	13915-13916	.	_	
79-18	13917-13921	fMRI	_	
79-19	13922-13926	Data	_	
79-20	13927-13935	analyses	_	
79-21	13936-13940	Data	_	
79-22	13941-13955	pre-processing	_	
79-23	13956-13959	and	_	
79-24	13960-13971	statistical	_	
79-25	13972-13980	analysis	_	
79-26	13981-13985	were	_	
79-27	13986-13995	conducted	_	
79-28	13996-14001	using	_	
79-29	14002-14006	FEAT	_	
79-30	14007-14008	(	_	
79-31	14008-14012	fMRI	_	
79-32	14013-14019	Expert	_	
79-33	14020-14028	Analysis	_	
79-34	14029-14033	Tool	_	
79-35	14033-14034	)	_	
79-36	14035-14039	from	_	
79-37	14040-14043	the	_	
79-38	14044-14049	FMRIB	_	
79-39	14050-14058	Software	_	
79-40	14059-14066	Library	_	
79-41	14067-14068	(	_	
79-42	14068-14086	www.fmrib.ox.ac.uk	_	
79-43	14086-14087	/	_	
79-44	14087-14090	fsl	_	
79-45	14090-14091	)	_	
79-46	14091-14092	.	_	

